Brainvectis, A Subsidiary Of Asklepios Biopharmaceutical, Inc. (askbio)

This early-stage study is testing a one-time gene therapy called AB-1001, delivered directly into the brain, in a small group of adults with early Huntington's disease. The main goals are to see if the treatment is safe and to look for early signs that it might slow the disease. …